BACKGROUND: The optimal timing of highly active antiretroviral therapy (HAART) in human immunodeficiency virus (HIV)-infected patients with > or = 200 absolute CD4 lymphocytes/mm3 is unknown. CD4 lymphocyte percentage could add prognostic information. METHODS: Persons who initiated HAART between 1 January 1998 and 1 January 2003, received > or = 30 days of therapy, and had baseline CD4 lymphocyte data available were included in the study. The log-rank test for time to event and Cox proportional hazards models were used to determine predictors of a new acquired immunodeficiency syndrome-defining illness or death. RESULTS: A total of 788 patients met the inclusion criteria. At baseline, subjects had a median of 225 CD4 lymphocytes/mm3 and 17% CD4 lymphocytes. Subjects with < 17% CD4 lymphocytes had earlier disease progression, compared with subjects with > or = 17%, both in the entire cohort (P<.0001) and of those subjects with > 350 absolute CD4 lymphocytes/mm3 at baseline (P=.03). CD4 lymphocyte percentage < 17% was the strongest predictor of disease progression among subjects in this latter group (hazard ratio, 3.57; P=.045). CONCLUSIONS: In this cohort, CD4 lymphocyte percentage predicted disease progression in HIV-infected subjects who initiated therapy with > 350 CD4 lymphocytes/mm3. This information may help identify persons who will derive the greatest benefit from initiation of HAART.
BACKGROUND: The optimal timing of highly active antiretroviral therapy (HAART) in human immunodeficiency virus (HIV)-infectedpatients with > or = 200 absolute CD4 lymphocytes/mm3 is unknown. CD4 lymphocyte percentage could add prognostic information. METHODS:Persons who initiated HAART between 1 January 1998 and 1 January 2003, received > or = 30 days of therapy, and had baseline CD4 lymphocyte data available were included in the study. The log-rank test for time to event and Cox proportional hazards models were used to determine predictors of a new acquired immunodeficiency syndrome-defining illness or death. RESULTS: A total of 788 patients met the inclusion criteria. At baseline, subjects had a median of 225 CD4 lymphocytes/mm3 and 17% CD4 lymphocytes. Subjects with < 17% CD4 lymphocytes had earlier disease progression, compared with subjects with > or = 17%, both in the entire cohort (P<.0001) and of those subjects with > 350 absolute CD4 lymphocytes/mm3 at baseline (P=.03). CD4 lymphocyte percentage < 17% was the strongest predictor of disease progression among subjects in this latter group (hazard ratio, 3.57; P=.045). CONCLUSIONS: In this cohort, CD4 lymphocyte percentage predicted disease progression in HIV-infected subjects who initiated therapy with > 350 CD4 lymphocytes/mm3. This information may help identify persons who will derive the greatest benefit from initiation of HAART.
Authors: S S Martinez; A Campa; H Bussmann; S Moyo; J Makhema; F G Huffman; O D Williams; M Essex; R Marlink; M K Baum Journal: Br J Nutr Date: 2016-04-18 Impact factor: 3.718
Authors: Cassidy W Claassen; Marie Diener-West; Shruti H Mehta; David L Thomas; Gregory D Kirk Journal: Clin Infect Dis Date: 2012-03-28 Impact factor: 9.079
Authors: Norman L Letvin; John R Mascola; Yue Sun; Darci A Gorgone; Adam P Buzby; Ling Xu; Zhi-Yong Yang; Bimal Chakrabarti; Srinivas S Rao; Jörn E Schmitz; David C Montefiori; Brianne R Barker; Fred L Bookstein; Gary J Nabel Journal: Science Date: 2006-06-09 Impact factor: 47.728
Authors: Nicola M Zetola; Beth Kaplan; Teri Dowling; Trevor Jensen; Brian Louie; Mahtab Shahkarami; Grant Colfax; Jeffrey D Klausner Journal: Public Health Rep Date: 2008 Nov-Dec Impact factor: 2.792
Authors: Danielle Cristyane Kalva Borato; Emerson Carraro; Sônia Regina Weber Ribas; Carlos Augusto Kalva-Filho; José Carlos Rebuglio Vellosa Journal: ScientificWorldJournal Date: 2012-11-28